Program overview
Context
Indication: Ph- Acute Lymphoblastic Leukemia (Ph-ALL)
Mechanism: Unknown
Modality: Unknown
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Low Signal
Inotuzumab Ozogamicin (IO)
Inotuzumab Ozogamicin (IO) is flagged as low signal because public records show limited public risk signal. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 0/5
Timeline: 0/5
Recruitment burden: 1/5
Results availability: 0/5
Program risk: 0/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT07643103
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT07643103 | Low Signal (NOT_YET_RECRUITING) | None | Low Signal | complex_intervention_signal |